📣 VC round data is live. Check it out!

Neuronetics Valuation Multiples

Discover revenue and EBITDA valuation multiples for Neuronetics and similar public comparables like Zomedica, Fractyl Health, Fonar, SDI Group and more.

Neuronetics Overview

About Neuronetics

Neuronetics Inc a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulations, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advanced Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address many of the key limitations of existing treatment options.


Founded

2003

HQ

United States

Employees

716

Financials (LTM)

Revenue: $154M
EBITDA: ($18M)

EV

$187M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Neuronetics Financials

Neuronetics reported last 12-month revenue of $154M and negative EBITDA of ($18M).

In the same LTM period, Neuronetics generated $74M in gross profit, ($18M) in EBITDA losses, and had net loss of ($37M).

Revenue (LTM)


Neuronetics P&L

In the most recent fiscal year, Neuronetics reported revenue of $149M and EBITDA of ($22M).

Neuronetics is unprofitable as of last fiscal year, with gross margin of 48%, EBITDA margin of (14%), and net margin of (26%).

See analyst estimates for Neuronetics
LTMLast FY202320242025202620272028
Revenue$154M$149M$71M$75M$149M
Gross Profit$74M$72M$52M$54M$72M
Gross Margin48%48%72%72%48%
EBITDA($18M)($22M)($23M)($35M)($28M)
EBITDA Margin(12%)(14%)(33%)(47%)(19%)
EBIT Margin(19%)(21%)(43%)(46%)(21%)
Net Profit($37M)($39M)($30M)($44M)($39M)
Net Margin(24%)(26%)(42%)(58%)(26%)
Net Debt—$38M———

Financial data powered by Morningstar, Inc.

Neuronetics Stock Performance

Neuronetics has current market cap of $115M, and enterprise value of $187M.

Market Cap Evolution


Neuronetics' stock price is $1.65.

Neuronetics share price decreased by 14.7% in the last 30 days, and by 57.7% in the last year.

Neuronetics has an EPS (earnings per share) of $-0.56.

See more trading valuation data for Neuronetics
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$187M$115M-9.8%-14.7%23.5%-57.7%$-0.56

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Neuronetics Valuation Multiples

Neuronetics trades at 1.2x EV/Revenue multiple, and (10.3x) EV/EBITDA.

See NTM and 2027E valuation multiples for Neuronetics

EV / Revenue (LTM)


Neuronetics Financial Valuation Multiples

As of May 9, 2026, Neuronetics has market cap of $115M and EV of $187M.

Neuronetics has a P/E ratio of (3.1x).

LTMLast FY202320242025202620272028
EV/Revenue1.2x1.3x2.6x2.5x1.3x
EV/EBITDA(10.3x)(8.7x)(8.0x)(5.3x)(6.7x)
EV/EBIT(6.4x)(6.0x)(6.1x)(5.4x)(6.0x)
EV/Gross Profit2.5x2.6x3.6x3.5x2.6x
P/E(3.1x)(3.0x)(3.8x)(2.6x)(3.0x)
EV/FCF—(8.8x)(5.4x)(5.8x)(8.8x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Neuronetics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Neuronetics Margins & Growth Rates

Neuronetics grew revenue by 9% but EBITDA decreased by 43% in the last fiscal year.

In the most recent fiscal year, Neuronetics reported gross margin of 48%, EBITDA margin of (14%), and net margin of (26%).

See estimated margins and future growth rates for Neuronetics

Neuronetics Margins

Last FY202420252026202720282029
Gross Margin48%72%48%48%
EBITDA Margin(14%)(47%)(19%)(8%)
EBIT Margin(21%)(46%)(21%)(15%)
Net Margin(26%)(58%)(26%)(20%)
FCF Margin(14%)(43%)(14%)—

Neuronetics Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth9%5%99%9%
Gross Profit Growth7%5%34%7%
EBITDA Growth(43%)51%(20%)(56%)
EBIT Growth(21%)13%(9%)(21%)
Net Profit Growth(17%)45%(11%)(17%)
FCF Growth—(6%)(35%)—

Data powered by FactSet, Inc. and Morningstar, Inc.

Neuronetics Operational KPIs

Neuronetics' revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.

Neuronetics' Rule of 40 is 1% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Neuronetics' Rule of X is 14% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Neuronetics
LTMLast FY202320242025202620272028
Rule of 40(2%)1%———
Bessemer Rule of X13%14%———
Revenue per Employee—$0.2M———
Opex per Employee—$0.1M———
S&M Expenses to Revenue31%32%66%61%32%
G&A Expenses to Revenue32%33%36%40%33%
R&D Expenses to Revenue4%4%13%17%4%
Opex to Revenue—70%115%118%70%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Neuronetics Competitors

Neuronetics competitors include Zomedica, Fractyl Health, Fonar, SDI Group, C-Rad, Rapid Micro Biosystems, Vuno, Paxman, Onyx Healthcare and Sedana Medical.

Most Neuronetics public comparables operate across Medical Devices.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Zomedica2.1x2.1x(3.3x)—
Fractyl Health——(1.1x)(1.1x)
Fonar1.0x—5.7x—
SDI Group1.7x1.5x9.4x7.8x
C-Rad2.1x2.1x17.1x15.3x
Rapid Micro Biosystems3.2x3.0x(2.5x)(2.5x)
Vuno4.4x—(42.0x)—
Paxman3.2x2.9x34.5x22.7x

This data is available for Pro users. Sign up to see all Neuronetics competitors and their valuation data.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Neuronetics

When was Neuronetics founded?Neuronetics was founded in 2003.
Where is Neuronetics headquartered?Neuronetics is headquartered in United States.
How many employees does Neuronetics have?As of today, Neuronetics has over 716 employees.
Who is the CEO of Neuronetics?Neuronetics' CEO is Keith J. Sullivan.
Is Neuronetics publicly listed?Yes, Neuronetics is a public company listed on Nasdaq.
What is the stock symbol of Neuronetics?Neuronetics trades under STIM ticker.
When did Neuronetics go public?Neuronetics went public in 2018.
Who are competitors of Neuronetics?Neuronetics main competitors include Zomedica, Fractyl Health, Fonar, SDI Group, C-Rad, Rapid Micro Biosystems, Vuno, Paxman, Onyx Healthcare, Sedana Medical.
What is the current market cap of Neuronetics?Neuronetics' current market cap is $115M.
What is the current revenue of Neuronetics?Neuronetics' last 12 months revenue is $154M.
What is the current revenue growth of Neuronetics?Neuronetics revenue growth (NTM/LTM) is 10%.
What is the current EV/Revenue multiple of Neuronetics?Current revenue multiple of Neuronetics is 1.2x.
Is Neuronetics profitable?No, Neuronetics is not profitable.
What is the current EBITDA of Neuronetics?Neuronetics has negative EBITDA and is not profitable.
What is Neuronetics' EBITDA margin?Neuronetics' last 12 months EBITDA margin is (12%).
What is the current EV/EBITDA multiple of Neuronetics?Current EBITDA multiple of Neuronetics is (10.3x).
How many companies Neuronetics has acquired to date?Neuronetics hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Neuronetics has invested to date?Neuronetics hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Neuronetics

Lists including Neuronetics

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial